Leveraging Adeno-Associated Viruses (AAVs) in therapeutic approaches for monogenic neurological diseases
Supplied by PerkinElmer on Wednesday, 07 September, 2022
Within the field of neurological diseases, there is great interest in looking at rare diseases of monogenic origin with the hope of developing disease-modifying gene therapies, as opposed to treatments for symptom management. Therefore, using relatively tunable systems like recombinant AAVs, scientists are also exploring in vivo gene delivery in parallel to ex vivo.
Learn about key strategies and innovations in this space that are enabling advanced gene therapy.
Related White Papers
Assessing yeast viability
Microorganisms such as yeast are used in many biotechnology applications including genetic...
[eBook] Therapeutic proteins: bioprocessing methods for mAb generation
How to optimise your bioprocess for monoclonal...
Protective solutions for glove allergies
Wearing glove products can cause adverse skin reactions, ranging from irritant contact...
